Sarepta Therapeutics plans to submit applications to convert Amondys 45 and Vyondys 53 from accelerated to traditional approvals for DMD. Wall Street analysts view this as a positive step that removes market withdrawal risks. The submission, supported by confirmatory trial data, strengthens the long-term outlook for these two Duchenne muscular dystrophy therapies.